A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis

Inclusion Criteria:

1. Signed informed consent must be obtained prior to participation in the study

2. Male or female patients aged ≥18 years at enrollment

3. Diagnosis of MS according to the 2017 revised McDonald criteria (Thompson et al 2018b)

4. RMS with active disease as defined by Lublin et al. (2014)

5. Max. 1 relapse during the previous year and max. 2 relapses during the previous twoyears prior to enrollment

6. Disability status at enrollment with an EDSS score of 0 to 2.5 (inclusive)

7. Planned initiation or initiation within the past 14 days with an approved injectableDMT for MS as routine medical treatment

Exclusion Criteria:

1. Patients being treated outside of the approved label

2. > 5 years since first symptom(s) (leading to MS diagnosis) at enrollment

3. Previous therapy with any DMT for the treatment of MS prior to enrollment (exceptwithin the past 14 days with an approved injectable DMT for MS as routine medicaltreatment; see Inclusion criteria #7)

4. Relapse prior to enrollment which has led to a severe deficit relevant to everydaylife upon discretion of the investigator after exhaustion of the relapse therapy

5. Poor recovery from the first two relapses prior to enrollment upon discretion of theinvestigator

6. EDSS Functional System Score "Pyramidal Functions" ≥ 2 at enrollment

7. Simultaneous participation in any investigational trial or simultaneousparticipation in another Novartis-sponsored non-interventional study with Ofatumumab